Shuo Chen
Ludwig Institute for Cancer Research
4 Papers
7 Citations
Shuo Chen is an academic researcher from Ludwig Institute for Cancer Research. The author has contributed to research in topics: Neutralizing antibody & Antibody. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys.
Shuang Wang,Yun Peng,Rongjuan Wang,Shasha Jiao,Min Wang,Weijin Huang,Chao Shan,Wen Jiang,Zepeng Li,Chunying Gu,Ben Chen,Xue Hu,Yanfeng Yao,Juan Min,Huajun Zhang,Ying Chen,Ge Gao,Peipei Tang,Gang Li,An Wang,Lan Wang,Jinchao Zhang,Shuo Chen,Xun Gui,Zhiming Yuan,Datao Liu +25 more
TL;DR: A monoclonal antibody, MW05, with SARS-CoV-2 neutralizing activity by disrupting the interaction of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor is reported.
Functional and molecular features of the calmodulin-interacting protein IQCG required for haematopoiesis in zebrafish.
Li-Ting Chen,Wen-Xue Liang,Shuo Chen,Ren-Ke Li,Jue-Ling Tan,Peng-Fei Xu,Liu-Fei Luo,Lei Wang,Shan-He Yu,Guoyu Meng,Keqin Kathy Li,Ting Xi Liu,Zhu Chen,Sai-Juan Chen,Sai-Juan Chen +14 more
TL;DR: It is found that the numbers of haematopoietic stem cells and multilineage-differentiated cells are reduced in iqcg-deficient embryos and a model in which IQCG stores CaM at low cytoplasmic calcium concentrations, and releases CaM to activate CaMKIV when calcium level rises is proposed.
An antibody-dependent enhancement (ADE) activity eliminated neutralizing antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
Shuang Wang,Yun Peng,Rongjuan Wang,Shasha Jiao,Min Wang,Weijin Huang,Chao Shan,Wen Jiang,Zepeng Li,Chunying Gu,Ben Chen,Xue Hu,Yanfeng Yao,Juan Min,Huajun Zhang,Ying Chen,Ge Gao,Peipei Tang,Gang Li,An Wang,Lan Wang,Shuo Chen,Xun Gui,Jinchao Zhang,Zhiming Yuan,Datao Liu +25 more
TL;DR: A monoclonal antibody, MW05, is reported showing high SARS-CoV-2 neutralizing activity by disrupting the interaction of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor by introducing the LALA mutation to the Fc region (MW05/LALA).
7
Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction
Shuang Wang,Junchao Wang,Xiaojuan Yu,Wen Jiang,Shuo Chen,Rongjuan Wang,Mingzhu Wang,Shasha Jiao,Ying Yang,Wenbo Wang,Huilin Chen,Ben Chen,Chunying Gu,Chang Liu,An Wang,Min Wang,Gang Li,Cuicui Guo,Datao Liu,Jinchao Zhang,Min Zhang,Lan Wang,Xun Gui +22 more
TL;DR: In this article , two neutralizing mAbs, MW01 and MW05, could enhance the infection of SARS-CoV-2 pseudovirus on FcγRIIB-expressing B cells.